NRAS and colorectal carcinoma: Based on these findings, we prospectively assessed if selecting cases with noncodon 12 KRAS/NRAS mutations and noncodon 600 BRAF mutation would increase the prevalence of POLE‐mutated MMR‐P CRC in the exonuclease domain compared with an unselected population.